For the quarter ending 2025-09-30, ANIP has $1,408,152K in assets. $902,335K in debts. $262,610K in cash and cash equivalents.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 262,610 | 217,797 | ||
| Restricted cash | 36 | 36 | ||
| Accounts receivable, net of 125,165 and 127,824 of adjustments for chargebacks and other allowances at september30, 2025 and december31, 2024, respectively | 252,617 | 225,654 | ||
| Inventories | 146,475 | 138,315 | ||
| Prepaid income taxes | 9,254 | - | ||
| Prepaid expenses and other current assets | 18,551 | 15,110 | ||
| Investment in equity securities | 8,859 | 5,718 | ||
| Total current assets | 698,402 | 602,630 | ||
| Property and equipment, net | 63,560 | 59,247 | ||
| Deferred tax assets, net of deferred tax liabilities and valuation allowance | 71,396 | 92,025 | ||
| Total | 499,817 | - | ||
| Gross carrying amount-In Process Research And Development | 0 | - | ||
| Intangible assets, net | 499,817 | 520,320 | ||
| Goodwill | 62,480 | 60,533 | ||
| Derivatives and other non-current assets | 12,497 | 8,246 | ||
| Total assets | 1,408,152 | 1,343,001 | ||
| Current debt, net of deferred financing costs | 15,241 | 13,216 | ||
| Accounts payable | 69,795 | 54,569 | ||
| Accrued royalties | 51,247 | 36,030 | ||
| Accrued compensation and related expenses | 33,221 | 32,933 | ||
| Accrued government rebates | 37,032 | 32,866 | ||
| Income taxes payable | 0 | 3,294 | ||
| Returned goods reserve | 50,005 | 48,683 | ||
| Current contingent consideration | 63 | 483 | ||
| Accrued expenses and other | 13,951 | 14,761 | ||
| Total current liabilities | 270,555 | 236,835 | ||
| Non-current debt, net of deferred financing costs and current component | 297,677 | 301,484 | ||
| Non-current convertible notes, net of deferred financing costs | 307,392 | 306,862 | ||
| Non-current contingent consideration, net of current | 11,379 | 18,089 | ||
| Accrued licensor payments due | 4,062 | 11,428 | ||
| Other non-current liabilities | 11,270 | 6,696 | ||
| Total liabilities | 902,335 | 881,394 | ||
| Common stock, 0.0001 par value, 66,000,000 shares authorized 23,076,007 shares issued and 22,462,035 outstanding at september30, 2025 0.0001 par value, 33,333,334 shares authorized 21,537,707 shares issued and 21,108,152 shares outstanding at december31, 2024 | 3 | 2 | ||
| Treasury stock, 613,972 shares of common stock, at cost, at september30, 2025 and 429,555 shares of common stock, at cost, at december31, 2024 | 32,638 | 31,594 | ||
| Additional paid-in capital | 586,230 | 541,899 | ||
| Accumulated deficit | -50,589 | -76,862 | ||
| Accumulated other comprehensive income, net of tax | 2,811 | 3,312 | ||
| Total stockholders equity | 505,817 | 436,757 | ||
| Convertible preferred stock, series a, 0.0001 par value, 1,666,667 shares authorized 25,000 shares issued and outstanding at june30, 2025 and december31, 2024 | - | 24,850 | ||
| Total liabilities, mezzanine equity, and stockholders equity | 1,408,152 | 1,343,001 | ||
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)